Diffuse large-cell lymphoma

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Fisher, R I ^a,b  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autologous transplantation; CHOP; Diffuse large B cell lymphoma; IPI; NHL

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; VINCRISTINE;

CANCER RESEARCH; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

EID: 0034004109     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S29     Document Type: Conference Paper

References (21)

1. Fisher RI. Hubbard SM. DeVita VTet al. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981; 58: 45-51.
2. Coltman CA, Dahlberg S. Jones SE et al. Southwest Oncology Group Studies in diffuse large-cell lymphoma: A subset analysis. In Kimura K (ed): Cancer Chemotherapy: Challenges for the Future. Tokyo: Excerpta Medica 1988; 194-202.
3. Shipp MA, Harrington DP, Klatt MM et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-65.
4. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
5. Longo DL, DeVita VT, Duffey PL et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 1991; 9: 25-38.
6. Fisher RI. Miller TP, Dana BW et al. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol 1987; 24: 21-25.
7. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
8. Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeulic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-9.
9. Cooper IA, Wolf MM, Robertson TI et al. Randomized comparison of MACOP-B and CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 769-78.
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993: 329: 987-94.
11. Gordon LI, Andersen J. Habermann TM et al. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACE-CytaBOM. J Clin Oncol 1996; 14: 1275-81.
12. Shipp MA, Neuherg D. Janicek M et al. High-dose CHOP as. initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 1995; 13: 2916-23.
13. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
14. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-32.
15. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
16. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
17. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous hone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-7.
18. Haioun C, Lepage E. Gisselhrechl C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994; 12: 2543-51.
19. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 1997; 15: 1131-7.
20. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 1998: 16: 2796-802.
21. Reyes F, Lepage E. Morel P et al. Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients with aggressive lymphomas: Updated results of the randomized LNH93-3 study. Blood 1997; 90: 594a (Abstr).